Advanced search    

Search: authors:"Marja-Riitta Taskinen"

44 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

and CVD risk. Conflict of Interest Marja-Riitta Taskinen declares personal fees from Amgen, AstraZeneca, and Chiesi Pharma, grant support and personal fees from Sanofi Aventis and Novo Nordisk, and

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models

Context Mathematical models may help the analysis of biological systems by providing estimates of otherwise un-measurable quantities such as concentrations and fluxes. The variability in such systems makes it difficult to translate individual characteristics to group behavior. Mixed effects models offer a tool to simultaneously assess individual and population behavior from...

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men

Context Glucose and lipids stimulate the gut-hormones glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent insulinotropic polypeptide (GIP) but the effect of these on human postprandial lipid metabolism is not fully clarified. Objective To explore the responses of GLP-1, GLP-2 and GIP after a fat-rich meal compared to the same responses after an oral glucose tolerance test...

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

Aims/hypothesis Baseline circulating fibroblast growth factor 21 (FGF21) levels can predict total cardiovascular disease events in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. This paper describes the relationship of baseline FGF21 levels and new on-study microvascular disease in patients with type 2 diabetes from the FIELD study. Methods Baseline...

Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study

OBJECTIVE To study the ability of lipid variables to predict incident coronary artery disease (CAD) events in patients with type 1 diabetes at different stages of nephropathy.

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model

manuscript. Acknowledgements Thanks go to Michaela Ho hne from the University of Kaiserslautern for her help in preparing the figures. Data was generated by Martin Adiels, Professor Marja-Riitta Taskinen

Effect of HDL composition and particle size on the resistance of HDL to the oxidation

Objectives To study the resistance of HDL particles to direct oxidation in respect to the distribution of HDL particles. Design and Methods We studied HDL composition, subclass distribution, and the kinetics of CuSO4-induced oxidation of total HDL and HDL3 in vitro in 36 low-HDL-C subjects and in 41 control subjects with normal HDL-C. Results The resistance of HDL3 to oxidation...

Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects

ContextNonfasting (postprandial) triglyceride concentrations have emerged as a clinically significant cardiovascular disease risk factor that results from accumulation of remnant triglyceride-rich lipoproteins (TRLs) in the circulation. The remnant TRLs are cleared from the circulation by hepatic uptake, but the specific mechanisms involved are unclear. The syndecan-1 heparan...

Cardiac steatosis and left ventricular function in men with metabolic syndrome

Hakkarainen Reijo Sirn Markku S Nieminen Marja-Riitta Taskinen Nina Lundbom Kirsi Lauerma 0 0 Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital and University of

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy

CAROL FORSBLOM DMSC ANNE HIUKKA EEVA S. LEINONEN PHD JOUKO SUNDVALL MSC PER-HENRIK GROOP PHD MARJA-RIITTA TASKINEN PHD OBJECTIVE - Although fenofibrate was associated with less progression of

Patients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals

Background A high-fat diet promotes postprandial systemic inflammation and metabolic endotoxemia. We investigated the effects of three consecutive high-fat meals on endotoxemia, inflammation, vascular function, and postprandial lipid metabolism in patients with type 1 diabetes. Methods Non-diabetic controls (n = 34) and patients with type 1 diabetes (n = 37) were given three high...

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

Background Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events.We aimed to establish whether CVD event rates were influenced by the metabolic syndrome as defined by the World Health Organisation (WHO), the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP...

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

MATHIJS C. BUNCK ANJA CORNR BJORN ELIASSON PHD ROBERT J. HEINE PHD RIMMA M. SHAGINIAN MARJA-RIITTA TASKINEN PHD ULF SMITH PHD HANNELE YKI-JRVINEN PHD MICHAELA DIAMANT PHD OBJECTIVEWe previously

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy

In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit over placebo in the primary endpoint of coronary heart disease events. Increased levels of atherogenic homocysteine were observed in some patients assigned to fenofibrate therapy but the molecular mechanisms behind this are poorly understood. Herein we investigated HDL lipidomic...

Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort

JAMES D. BEST PAUL L. DRURY FRACP TIMOTHY M.E. DAVIS MRCP MARJA-RIITTA TASKINEN Y. ANTERO KESNIEMI RUSSELL SCOTT PHD FRACP C a r d i o v a s c u l a r a n d OBJECTIVEdGlycemic control in type 2

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

MATHIJS C. BUNCK MICHAELA DIAMANT PHD BJORN ELIASSON PHD ANJA CORNER RIMMA M. SHAGINIAN ROBERT J. HEINE PHD MARJA-RIITTA TASKINEN PHD HANNELE YKI-J ARVINEN PHD ULF SMITH PHD OBJECTIVE To study the

IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: Response to Conti et al.

research is needed to understand the entire picture. PEKKA J. LEINONEN, MD, PHD2 MARJA-RIITTA TASKINEN, MD, PHD1 EEVA S. LEINONEN, MD1 From the 1Department of Internal Medicine, Helsinki University Central

Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis

Association testing of multiple correlated phenotypes offers better power than univariate analysis of single traits. We analyzed 6,600 individuals from two population-based cohorts with both genome-wide SNP data and serum metabolomic profiles. From the observed correlation structure of 130 metabolites measured by nuclear magnetic resonance, we identified 11 metabolic networks and...

An Immune Response Network Associated with Blood Lipid Levels

Michael Inouye Kaisa Silander Eija Hamalainen Veikko Salomaa Kennet Harald Pekka Jousilahti Satu Ma nnisto Johan G. Eriksson Janna Saarela Samuli Ripatti Markus Perola Gert-Jan B. van Ommen Marja-Riitta ... Taskinen Aarno Palotie Emmanouil T. Dermitzakis Leena Peltonen Gregory S. Barsh, Stanford University, United States of America While recent scans for genetic variation associated with human disease have